GSK3β inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons

被引:17
作者
Vazquez de la Torre, Aurelio [1 ]
Junyent, Felix [1 ,2 ]
Folch, Jaume [2 ]
Pelegri, Carme [3 ]
Vilaplana, Jordi [3 ]
Auladell, Carme [4 ]
Beas-Zarate, Carlos [5 ,6 ]
Pallas, Merce [1 ]
Verdaguer, Ester [4 ]
Carnins, Antoni [1 ]
机构
[1] Nucli Univ Pedralbes, Univ Barcelona, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Unitat Farmacol & Farmacognosia,Fac Farm,Inst Bio, Barcelona 08028, Spain
[2] Univ Rovira & Virgili, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Fac Med & Ciencies Salut, Unitat Bioquim, Reus 43201, Tarragona, Spain
[3] Univ Barcelona, Fac Farm, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Dept Fisiol, E-08028 Barcelona, Spain
[4] Univ Barcelona, Fac Biol, Dept Cellular Biol, Barcelona, Spain
[5] Univ Guadalajara, CUCBA, Dept Biol Celular & Mol, Guadalajara 44340, Jalisco, Mexico
[6] IMSS, CIBO, Div Neurociencias, Guadalajara 44340, Jalisco, Mexico
关键词
Flavopiridol; Roscovitine; GSK3; beta; Cerebellar granular cells; Apoptosis; GLYCOGEN-SYNTHASE KINASE-3; CEREBELLAR GRANULE CELLS; C-JUN; GSK-3; INHIBITORS; CDK INHIBITORS; CANCER-CELLS; ROSCOVITINE; APOPTOSIS; SURVIVAL; PHOSPHORYLATION;
D O I
10.1016/j.phrs.2011.08.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study, we evaluated the effects of roscovitine (Rosco) and flavopiridol (Flavo), both of which are classified as cyclin-dependent kinase (CDK) inhibitors, on apoptosis induced by the inhibition of PI3K/AKT pathway in cerebellar granule neurons (CGNs). Our results demonstrate that both CDK inhibitors prevented apoptosis induced by LY294002 (LY), as also occurs with SB415286 (SB4), a selective GSK3 beta inhibitor. Our findings also indicate that these CDK inhibitors inhibit GSK3 beta, representing a potential pharmacological mechanism involved in their neuroprotective properties. Thus, the increased activity of GSK3 beta induced by LY294002 and detected by dephosphorylation at Ser9 was prevented by both compounds. Likewise, GSK3 beta activity was measured by a radioactivity assay, revealing that CDK inhibitors and SB415286 prevented the increase in GSK3 beta activity induced by PI3K inhibition. In addition, we analysed c-Jun, which is also a mediator of PI3K inhibition-induced apoptosis. However, neither of the CDK inhibitors nor 513415286 prevented the increase in c-Jun phosphorylation induced by PI3K inhibition. Therefore, our data identify GSK3 beta as a crucial mediator of CGN apoptosis induced by PI3K inhibition and indicate that the antiapoptotic effects of CDKs are mediated by the inhibition of this pharmacological target. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:66 / 73
页数:8
相关论文
共 50 条
  • [31] A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies
    Thapa, Riya
    Gupta, Gaurav
    Bhat, Asif Ahmad
    Almalki, Waleed Hassan
    Alzarea, Sami I.
    Kazmi, Imran
    Saleem, Shakir
    Khan, Ruqaiyah
    Altwaijry, Najla
    Dureja, Harish
    Singh, Sachin Kumar
    Dua, Kamal
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 253
  • [32] The neuroprotective mechanism of puerarin in the treatment of acute spinal ischemia-reperfusion injury is linked to cyclin-dependent kinase 5
    Tian, Feng
    Xu, Li-Hui
    Wang, Bin
    Tian, Li-Jie
    Ji, Xiang-Lu
    [J]. NEUROSCIENCE LETTERS, 2015, 584 : 50 - 55
  • [33] Novel potent pharmacological cyclin-dependent kinase inhibitors
    Wesierska-Gadek, Jozefa
    Chamrad, Ivo
    Krystof, Vladimir
    [J]. FUTURE MEDICINAL CHEMISTRY, 2009, 1 (09) : 1561 - 1581
  • [34] Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
    Giannone, Gaia
    Tuninetti, Valentina
    Ghisoni, Eleonora
    Genta, Sofia
    Scotto, Giulia
    Mittica, Gloria
    Valabrega, Giorgio
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
  • [35] Cyclin-dependent kinase inhibitors closer to market launch?
    Galons, Herve
    Oumata, Nassima
    Gloulou, Olfa
    Meijer, Laurent
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (08) : 945 - 963
  • [36] Cyclin-dependent kinase inhibitors: novel anticancer agents
    Mani, S
    Wang, CG
    Wu, KM
    Francis, R
    Pestell, R
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (08) : 1849 - 1870
  • [37] Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS-032, on cervical cancer
    Kang, Mi Ae
    Kim, Wonwoo
    Jo, Hye-Ram
    Shin, Young-Joo
    Kim, Moon-Hong
    Jeong, Jae-Hoon
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (02) : 703 - 712
  • [38] Cyclin-dependent kinase 7 inhibitors in cancer therapy
    Wang, Minmin
    Wang, Tianyu
    Zhang, Xiangyu
    Wu, Xiaoxing
    Jiang, Sheng
    [J]. FUTURE MEDICINAL CHEMISTRY, 2020, 12 (09) : 813 - 833
  • [39] Cyclin-dependent kinase and protein kinase C inhibitors: A novel class of antineoplastic agents in clinical development
    Kaubisch, A
    Schwartz, GK
    [J]. CANCER JOURNAL, 2000, 6 (04) : 192 - 212
  • [40] DNA damage-dependent cyclin D1 proteolysis GSK3β holds the smoking gun
    Pontano, Laura L.
    Diehl, J. Alan
    [J]. CELL CYCLE, 2009, 8 (06) : 824 - 827